Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology

被引:160
作者
Suchowersky, O
Gronseth, G
Perlmutter, J
Reich, S
Zesiewicz, T
Weiner, WJ
机构
[1] Univ Calgary, Calgary, AB, Canada
[2] Univ Kansas, Kansas City, KS USA
[3] Div Radiat Sci, St Louis, MO USA
[4] Univ Maryland Hosp, Baltimore, MD 21201 USA
[5] Movement Disorder Ctr, Tampa, FL USA
[6] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
关键词
D O I
10.1212/01.wnl.0000206363.57955.1b
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To define key issues in the management of Parkinson disease (PD) relating to neuroprotective strategies and alternative treatments, and to make evidence-based treatment recommendations. Methods: Two clinical questions were identified. 1) In a patient diagnosed with PD, are there any therapies that can slow disease progression? 2) Are there any nonstandard pharmacologic or nonpharmacologic therapies that have been shown to improve motor function in PD? Articles were classified according to a four-tiered level of evidence scheme. Recommendations were based on the evidence. Results and conclusions: 1. Levodopa does not appear to accelerate disease progression. 2. No treatment has been shown to be neuroprotective. 3. There is no evidence that vitamin or food additives can improve motor function in PD. 4. Exercise may be helpful in improving motor function. 5. Speech therapy may be helpful in improving speech volume. 6. No manual therapy has been shown to be helpful in the treatment of motor symptoms, although studies in this area are limited. Further studies using a rigorous scientific method are needed to determine efficacy of alternative therapies.
引用
收藏
页码:976 / 982
页数:7
相关论文
共 63 条
[1]
[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD002812
[2]
[Anonymous], COCHRANE DATABASE SY
[3]
[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858
[4]
Apaydin H, 2000, MOVEMENT DISORD, V15, P164, DOI 10.1002/1531-8257(200001)15:1<164::AID-MDS1028>3.0.CO
[5]
2-E
[6]
Surrogate endpoints in Parkinson's disease research [J].
Kevin M. Biglan ;
Robert G. Holloway .
Current Neurology and Neuroscience Reports, 2003, 3 (4) :314-320
[7]
PHYSICAL REHABILITATION IN NEUROLOGIC DISEASES [J].
BOHANNON, RW .
CURRENT OPINION IN NEUROLOGY, 1993, 6 (05) :765-772
[8]
Carter S, 2003, MOVEMENT DISORD, V18, P1089
[9]
CHANDLER C, 1999, BPS BOOKS, P256
[10]
Chen L, 1998, J Tradit Chin Med, V18, P23